Welcome to the e-CCO Library!

P344: What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis
Year: 2022
Source: ECCO'22
Authors: Zarchi, R.(1);Elgressy, A.(2);Ben-Horin, S.(2);Kopylov, U.(2);
Created: Friday, 11 February 2022, 3:52 PM
P345 Lack of anti-TNF drugs levels in fistula tissue: A reason for non-response in Crohn’s perianal fistula?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Adegbola1, M. Sarafian2, K. Sahnan1, A. Pechlivanis2, R. Phillips1, C. Knowles3, J. Haddow4, J. Warusavitarne1, O. Faiz1, P. Tozer1, E. Holmes2, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P345: Capsule endoscopy in the diagnostic process of suspected Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hennlich, B.(1)*;Madl, C.(2);Pachofszky, T.(2);
Created: Friday, 14 July 2023, 11:05 AM
P345: Food-related quality of life in adults with Inflammatory Bowel Disease is influenced by restrictive eating behaviour, disease activity and surgery: a prospective multi-centre study
Year: 2021
Source: ECCO'21 Virtual
Authors: Day, A.(1,2);Yao, C.K.(3);Costello, S.(2,4);Andrews, J.(2,5);Bryant, R.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P345: Impact of aphthous colitis at diagnosis on Crohn’s disease outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Delattre1*, I. Nion-Larmurier1, A. Bourrier1, C. Landman1, G. Le Gall2, J. Kirchgesner1, H. Sokol1, L. Beaugerie1, J. Cosnes1, P. Seksik1

Created: Thursday, 21 February 2019, 9:14 AM
P345: Inconsistency between electronic data of patient's adherence and self reported adherence score
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Broide E.*1,2, Ein Dor A.1,3, Ruhimovich N.4, Shitrit A.B.5, Benjaminov F.2, Matalon S.1,3, Shirin H.1,2, Konikoff F.M.3,6, Naftali T.6

Created: Wednesday, 20 February 2019, 10:36 AM
P345: Risk of long-term post-operative recurrence (POR) in Crohn’s disease patients with a first postoperative normal endoscopic assessment under thiopurine prevention
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Mañosa1,2, M. Puig1, P. F. Torres1, F. Cañete1, J. Troya3, M. Calafat1, D. Parés3, E. Cabré1,2, E. Domènech1,2

Created: Friday, 22 February 2019, 9:41 AM
P345: The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Macaluso, F.S.(1);Grova, M.(1);Saladino, M.(2);Demarzo, M.G.(3);Privitera, A.C.(4);Giangreco, E.(5);Garufi, S.(6);Renna, S.(1);Casà, A.(1);Ventimiglia, M.(7);Cappello, M.(2);Fries, W.(3);Orlando, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P345: The Great Continental Divide: use of anti-TNF therapy in paediatric inflammatory bowel disease is significantly different in North America compared with other parts of the world.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Church1, J. Hyams2, F. Ruemmele3, L. de Ridder4, D. Turner5, A. Griffiths*1, o.b.o. the International Paediatric IBD Network (PIBDNet)6

Created: Friday, 22 February 2019, 9:49 AM
P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Liefferinckx1,2, M. Fassin2, D. Thomas3, C. Minsart1,2, A. Cremer1,2, L. Amininejad1, V. Tafciu2, V. Wambacq1, A. Van Gossum1, D. Franchimont1,2

Created: Thursday, 30 January 2020, 10:12 AM
P346: Chronic pouch failure rates after close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis.
Year: 2022
Source: ECCO'22
Authors: Reijntjes, M.(1);de Jong, D.(2);Bocharewicz, E.(1);Elise, W.(2);Duijvestein , M.(3);Bemelman, W.(1);
Created: Friday, 11 February 2022, 3:52 PM
P346: Decreasing disparities in and use of systemic corticosteroid and disparities in use among paediatric patients with Crohn disease in a multicentre collaborative
Year: 2021
Source: ECCO'21 Virtual
Authors: Adler, J.(1);Kandavel, P.(2);Eder, S.(1);Saeed, S.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P346: Dietary practices and beliefs among parents of children with inflammatory bowel disease: preliminary results
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pituch-Zdanowska A.*1, Stawicka A.1, Jarocka-Cyrta E.2, Banaszkiewicz A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P346: Influence of diagnostic delay on ulcerative colitis characteristics at disease onset
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ramírez, C.(1);Barreiro-de Acosta, M.(2);Cabriada, J.L.(1);Rodríguez-Lago, I.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P346: Small bowel permeability improves with nutritional therapy in mild-to-moderate active paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Wine*1, G. Abitbol2, A. Assa3, R. Sigall Boneh4, R. Shaoul5, M. Kori6, S. Cohen7, S. Peleg8, H. Shamaly9, A. On10, P. Millman11, L. Abramas4, T. Ziv Baran12, J. Van Limbergen13, A. Levine4,12

Created: Friday, 22 February 2019, 9:41 AM
P346: Soluble transferrin receptor and its relation to anaemia in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Created: Friday, 22 February 2019, 9:49 AM
P346: The application of indocyanine green during robotic surgery for IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.V. Marino1*, A.L. Komorowski2

Created: Thursday, 21 February 2019, 9:14 AM
P347 Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Bejar1, G. Bastida Paz1,2, M. Aguas1,2, A. Garrido Marín1, R. Marques3, E. Valero Pérez1, J. del Hoyo Francisco1, L. Tortosa Seguí1, D. Muñoz Gómez1, J.L. Poveda3, P. Nos Mateu1,2

Created: Thursday, 30 January 2020, 10:12 AM
P347: Evaluation of step up therapy in patients with early ulcerative colitis: a prospective cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bossuyt P.*1,2, Baert F.3, Coenegrachts J.-L.4, De Vos M.5, Dewit O.6, Ferrante M.7, Fontaine F.8, Mana F.9, Vandervoort J.10, Moreels T.11 Belgian IBD Research and Development Group

Created: Wednesday, 20 February 2019, 10:36 AM
P347: Identification of a cut-off for persistent anti-infliximab antibodies as a predictor of response to infliximab monotherapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Del Nero*1, G. Bodini2, E. Giannini2, J. Anjali3, V. Savarino1, E. Savarino4

Created: Friday, 22 February 2019, 9:49 AM